Denali Therapeutics Inc. (DNLI) Stock
3 of the hedge funds AlphaScala tracks reported DNLI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $28.95M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own DNLI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.13M | $28.95M | -11% |
| Marshall Wace | 550K | $14.14M | -45% |
| Citadel Ken Griffin | 67K | $1.72M | -63% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Denali Therapeutics Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Chin Peter Scott | Chief Medical Officer | SELL | 1.7K | $37K |
| Sep 2, 26 | Thornberry Nancy | Director | SELL | 10.8K | $247K |
| Sep 2, 26 | Thornberry Nancy | Director | SELL | 615 | $15K |
| Sep 1, 26 | Schuth Alexander O. | COFO and Secretary | SELL | 2.8K | $65K |
| Aug 11, 26 | Schuth Alexander O. | COFO and Secretary | SELL | 2.9K | $72K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →DNLI price chart
Powered by TradingViewWhat does Denali Therapeutics Inc. do?
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to enable effective delivery across the blood-brain barrier, targeting challenging central nervous system disorders. Its pipeline includes programs like DNL310 (Tividenofusp alfa) for Hunter syndrome (MPS II), DNL126 for MPS IIIA (Sanfilippo Syndrome A), DNL343 (eIF2B activator) for amyotrophic lateral sclerosis, BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease, Eclitasertib (DNL758, RIPK1 inhibitor) for peripheral inflammatory diseases, and others such as TAK-594/DNL593 for frontotemporal dementia-granulin and initiatives targeting TREM2 and Tau. Denali Therapeutics Inc. advances these candidates through clinical development, emphasizing innovative solutions for unmet needs in neurology and rare genetic disorders. Founded in 2013 and headquartered in South San Francisco, California, it plays a key role in the biotechnology sector dedicated to neurodegeneration.